Received Jan 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (DAPTACEL) | SANOFI PASTEUR | UNK | 3CA55C1 | OT / RL |
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | — | OT |
reports that a patient was given both vaccines, due to administration of two similar products with no reported adverse event; Initial information received on 15-Jan-2026 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 5 months old male patient who was administered two similar products Diphtheria-15/Tetanus/5 Ac Pertussis Vaccine [Daptacel] and Diphtheria vaccine toxoid, HIB vaccine conj (menigococcal protein), Hepatitis b vaccine rHBsAg (yeast), Pertussis vaccine acellular 5-component, Polio vaccine inact 3v (Vero), Tetanus vaccine toxoid [Vaxelis] with no reported adverse event . The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included Rotavirus vaccine (Rotavirus vaccine) for Immunisation. On 15-Jan-2026, the patient received two similar products that is: 0.5 ml dose of suspect Diphtheria-15/Tetanus/5 Ac Pertussis Vaccine, Suspension for injection, lot 3CA55C1, expiry date: 30-Aug-2026, Frequency :once, strength: standard in the right vastus lateralis and on an unknown date received an unknown dose of suspect Diphtheria vaccine toxoid, HIB vaccine conj (menigococcal protein), Hepatitis b vaccine rHBsAg (yeast), Pertussis vaccine acellular 5-component, Polio vaccine inact 3v (Vero), Tetanus vaccine toxoid not produced by Sanofi Pasteur, unknown formulation, lot number, strength and expiry date not reported in unknown administration site, both via unknown route with no reported adverse event (extra dose administered) (latency: same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Rotavirus vaccine